ARQ Genetics

Executive Summary

ARQ Genetics is a U.S.-based private company specializing in custom qPCR and RT-PCR gene expression analysis for academic and veterinary researchers. Founded in 2018 and headquartered in San Diego, the company differentiates itself through high-quality, bespoke assay design led by Ph.D.-level scientists, offering fast turnaround and publication-ready data. Serving a niche but critical segment of the research community, ARQ Genetics enables clients to accelerate their gene expression studies without the overhead of in-house assay development. The company operates in the expanding genomics services market, driven by increasing research funding and the growing importance of gene expression analysis in fields such as oncology, infectious disease, and veterinary science. Despite being a small private entity with no disclosed funding or detailed financials, ARQ Genetics benefits from recurring demand from academic labs and a reputation for scientific rigor. However, it faces competition from larger contract research organizations and in-house solutions. Key risks include dependence on a limited customer base and potential pricing pressure from larger players. With no catalyst events identified, the near-term outlook hinges on sustaining client relationships and capitalizing on the broader trend of outsourcing specialized research services.

Upcoming Catalysts (preview)

• Q4 2026Expansion into pharmaceutical and biotech clientele25% success
• Q2 2027Launch of a high-throughput qPCR service to compete with larger CROs15% success
• TBDStrategic partnership with a veterinary diagnostics company30% success